Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255464 | 0.83 | CHRNB2 (0.58) | LTA4HFLT3TYRO3MERTKGAS6 | |
| SCHEMBL20070838 | 0.80 | CHRNB2 (0.60) | LTA4HFLT3TYRO3MERTKGAS6 | |
| SCHEMBL22031253 | 0.80 | CHRNB2 (0.60) | LTA4HFLT3TYRO3MERTKGAS6 | |
| SCHEMBL20069992 | 0.80 | CHRNB2 (0.60) | LTA4HFLT3TYRO3MERTKGAS6 | |
| SCHEMBL20069989 | 0.80 | CHRNB2 (0.60) | LTA4HFLT3TYRO3MERTKGAS6 | |
| Hydrochloric Acid SCHEMBL20136938 | 0.79 | CHRNB2 (0.59) | LTA4HFLT3TYRO3MERTKGAS6 | |
| Hydrochloric Acid SCHEMBL31458823 | 0.79 | CHRNB2 (0.59) | LTA4HFLT3TYRO3MERTKGAS6 | |
| SCHEMBL22425611 | 0.78 | LTA4H (0.47) | LTA4HTLR7CHRNB2CHRNA4P2RX7 | |
| SCHEMBL20249267 | 0.75 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14216743 | 0.75 | CHRNB2 (0.56) | LTA4HCHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | LTA4H 3374/4885FLT3 289/4885TYRO3 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.